GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...
In October, when GSK agreed to a $2.2 billion settlement to resolve approximately 80,000 lawsuits | With a $2.2 billion ...
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
The pharmaceutical giant targets an increase in core operating profit of between 6% and 8% in 2025, after cancer treatments ...
As part of a new series looking at how pharma has responded to the pandemic, Neale Belson, SVP UK & Ireland and general manager for the UK at GSK, tells us that it is “absolutely critical” to ...
And, while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways to build past the GLP-1 space. GSK started this year’s J.P. Morgan ...
Hosted on MSN1mon
‘I’m not trying to turn GSK into Google’: How GSK’s Silicon Valley veteran has transformed the pharma giant into a tech powerhouseGSK’s chief digital and technology officer (CDTO) worked for years at tech giants like Apple and Salesforce before making the switch to the increasingly tech-savvy pharmaceutical sector.
GSK was forced to pay around £1.8bn to settle thousands of cases in US courts in October amid claims Zantac caused cancer. Pharmaceutical giant GSK has hiked its 2031 sales forecast to more than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback